Literature DB >> 18528513

The cancer treatment revolution.

David G Nathan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18528513      PMCID： PMC1863594     

Source DB:  PubMed          Journal:  Trans Am Clin Climatol Assoc        ISSN： 0065-7778


× No keyword cloud information.
  25 in total

1.  The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors.

Authors:  Dennis J Slamon
Journal:  Oncologist       Date:  2004

2.  Uninfected vertebrate cells contain a protein that is closely related to the product of the avian sarcoma virus transforming gene (src).

Authors:  H Oppermann; A D Levinson; H E Varmus; L Levintow; J M Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  1979-04       Impact factor: 11.205

3.  Nucleotide sequences related to the transforming gene of avian sarcoma virus are present in DNA of uninfected vertebrates.

Authors:  D H Spector; H E Varmus; J M Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  1978-09       Impact factor: 11.205

4.  Interstitial cells of Cajal in the human fetal small bowel as shown by c-kit immunohistochemistry.

Authors:  T Wester; L Eriksson; Y Olsson; L Olsen
Journal:  Gut       Date:  1999-01       Impact factor: 23.059

5.  KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.

Authors:  B P Rubin; S Singer; C Tsao; A Duensing; M L Lux; R Ruiz; M K Hibbard; C J Chen; S Xiao; D A Tuveson; G D Demetri; C D Fletcher; J A Fletcher
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

6.  Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells.

Authors:  F W Alt; R E Kellems; J R Bertino; R T Schimke
Journal:  J Biol Chem       Date:  1978-03-10       Impact factor: 5.157

Review 7.  Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia.

Authors:  B Druker
Journal:  Semin Hematol       Date:  2001-07       Impact factor: 3.851

Review 8.  Modelling the molecular circuitry of cancer.

Authors:  William C Hahn; Robert A Weinberg
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

9.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

10.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245
View more
  1 in total

1.  Modeling timelines for translational science in cancer; the impact of technological maturation.

Authors:  Laura M McNamee; Fred D Ledley
Journal:  PLoS One       Date:  2017-03-27       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.